In 2014, it was published an intriguing report [232], in which it was described that a novel high sensitive (hs) GH assay (detecting pg/mL, instead of the usual ng/mL of standard assays) correlated the number of hs-GH peaks with high cardiovascular morbidity and mortality (CAD, Stroke, Congestive Heart Failure) in a high population of Swedish patients. Here, GH1 is linked to coronary artery disorder.